Because of the potential of novobiocin-rifampin for oral therapy of methicillin-resistant Staphylococcus aureus infection, we evaluated the pharmacokinetics of novobiocin and rifampin, alone and in combination, in a randomized, crossover, multiple-dose evaluation (500 mg of novobiocin and 300 mg of rifampin administered orally, twice a day, for 27 doses) in 10 volunteers. The half-lives of novobiocin and rifampin when administered alone were 5.85 i 1.20 and 1.46 ± 0.30 h, respectively; when administered in combination, the half-lives were 2.66 ± 0.65 and 1.43 ± 0.29 h, respectively. This difference was significant for novobiocin. The area under the curve also differed significantly for novobiocin when administered in combination. No significant differences were seen in the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, or both for either drug when single and combination therapy groups were compared. A change in clearance of novobiocin rather than a change in absorption is the more likely explanation for these findings. The mechanism remains to be elucidated. Nevertheless, the trough serum concentrations of both novobiocin and rifampin were in excess of the MIC for 90% of strains tested of methicillin-resistant S. aureus, even when coadministered.
coadministered.
Methicillin-resistant Staphylococcus aureus has emerged as an important nosocomial pathogen in many hospitals across the United States (5, 10) . Currently, vancomycin is the drug of choice for the treatment of this infection. However, it would be desirable to have therapeutic alternatives, especially those which can be administered orally, for the treatment of this infection. Novobiocin has been used successfully in the past for the treatment of staphylococcal infections (8) . Emergence of resistance, however, occurred when novobiocin was used alone (6, 7) .
Rifampin is another antibiotic which is administered orally and which demonstrates excellent activity against methicillin-resistant staphylococci in vitro (13) . However, rapid emergence of resistance to rifampin also occurs when it is used as a single agent.
Results of preliminary work performed in this laboratory indicate that the combination of novobiocin-rifampin not only has excellent microbiologic activity against methicillinresistant S. aureus but that this combination of agents may prevent emergence of resistance (12, 13) . Consequently, the combination of novobiocin-rifampin holds promise as a therapeutic alternative to vancomycin for the treatment of methicillin-resistant S. aureus infections and for eradication of infection in patients colonized with these organisms.
Prior to the clinical study of this combination, it is necessary to determine the serum concentration-time profiles and pharmacokinetic parameters of each agent and to characterize the nature and extent of drug-drug interactions and possible toxicity in vivo. Consequently, we undertook a randomized, double-blind, crossover evaluation of niovobiocin and rifampin alone and in combination in 10 healthy males who received 500 mg of novobiocin by mouth twice a day, 300 mg of rifampin by mouth twice a day, or the * Corresponding author. combination of both drugs, for a total of 2 weeks per regimen.
MATERIALS AND METHODS
Subjects and treatment groups. Ten healthy, nonobese male volunteers between the ages of 18 and 55 years were selected. All subjects underwent a comprehensive physical examination and provided a complete medical history before acceptance into the study. Those Drug assay. The novobiocin assay was performed as a variant of the high-pressure liquid chromatographic assay developed by Tsuji and colleagues (11) . The method was validated for the novobiocin assay with and without rifampin. The assay sensitivity was 0.1 ,ug/ml. The interassay coefficient of variation was 2.9% at 1 ,ug/ml in the absence of rifampin. The coefficient of variation was 3.9% at 1 ,ug/ml in the presence of 35 ,ug of rifampin per ml. The interassay coefficient of variation was 4.2% at 10 ,ug of novobiocin per ml in the absence of rifampin. In the presence of 35 pug of rifampin per ml, the coefficient of variation at 10 ,ug of rbovobiocin per ml was 4.5%.
For rifampin, a variant of the high-pressure liquid chromatographic assay developed by Ratti et al. (9) was used. The assay was validated with and without novobiocin. The sensitivity of the assay was 0.1 ,g/ml. The interassay coefficient of variation was 6.1% for rifampin at 2 p,g/ml in the absence of novobiocin. The coefficient of variation was 8.3% at 2 ,ug of rifampin per ml assayed in the presence of 15 jig of novobiocin per ml. The interassay coefficient of variation was 2.1% at 20 ,ug/ml. This value was 7.3% at 20 ,ug of rifampin per ml assayed in the presence of 15 ,ug of novobiocin per ml.
Pharmacokinetic analysis. The maximum concentration in serum (Cmax) and the time to maxirnum concentration in serum (Tmax) were determined by inspection of individual serum concentration-time data for each patient. The area under the curve (AUC) was determined by the trapezoidal rule. As a steady-state dosing interval was being examined in all cases, no extrapolation to infinity was performed. The terminal elimination rate constant (kel) was determined from the terminal portion of the concentration-time curve. An iterative, weighted, nonlinear, least-squares regression analysis employing a Nelder-Meade simplex algorithm was used (4). The terminal elimination half-life (t112) was calculated as the natural logarithm of 2 divided by kel.
Statistical comparisons. For both drugs, analysis of variance was employed to test significance of differences in the concentrations that were achieved, when administered alone versus in combination. Similarly, the steady-state AUC from 0 to 12 h, Cmax, Tmax, kel, and t1/2 were compared for each drug when given alone versus in combination. An alpha value of 0.05 was deemed appropriate to determine the significance of the differences observed.
RESULTS
The mean (±standard deviation [SD]) serum concentration-time profiles for novobiocin alone and in the presence of rifampin are presented in Fig. 1 . The mean (+SD) predose serum concentration prior to dose 27 of novobiocin alone was 21.6 ± 6.7 jig/ml. This contrasts to a mean of 6.9 ± 5.6
,ug/ml for novobiocin coadministered with rifampin. Two hours after drug administration, a time approximating the Tmax, the mean concentration was 55.5 ± 17.1 ,ug/ml when novobiocin was administered alone. When given in combination, this value was 49.2 + 19.0 ,ug/ml. Eight hours after drug administration, the concentrations were 21.6 ± 6.7 ,ug/ml for novobiocin alone and 7.9 ± 3.9 ,g/ml for novobiocin in combination with rafampin. Twelve hours after drug administration, these values were 16.0 ± 5.1 ,ug/ml and 3.0 ± 1.4 ,ug/ml for novobiocin alone and in combination, respectively. Among the pharmacokinetic paramaters, Cmax and Tmax did not differ between novobiocin treatment groups. However, the AUC was highly significantly different (407 ,ug. h/ml for novobiocin and 225 ,ug. h/ml for novobiocin in combination; P < 0.0001). In addition, the kel and t1/2 were both significantly different between treatment groups, with the combination therapy group having the largest kei and shortest t1/2 for novobiocin (for both values, P < 0.01).
DISCUSSION
Methicillin-resistant S. aureus has emerged as a significant pathogen, particularly in nosocomial infections (5, 10 susceptible and -resistant S. aureus (13) . In addition, the drug combination prevents the emergence of resistance in vitro to each drug in the combination (12) . Little work has been done in which modem technology is used to document the serum concentration-time profile for novobiocin. No information is available regarding possible interactions when novobiocin and rifampin are administered together. Therefore, before embarking on a clinical trial with this drug combination, for patients either infected or colonized with methicillin-resistant S. aureus, we determined that it is necessary to do a study in which the serum concentrations of both drugs achieved at steady state are evaluated.
Serum concentrations of novobiocin exceed the MIC for 90% of strains tested of methicillin-resistant S. aureus for the whole dosing interval, when administered either alone or in combination. However, the serum concentrations and, consequently, the AUC developed in the serum were significantly lower in the group of patients receiving combination therapy. This is unlikely to be due to an interference with absorption, as the early points in the intensively sampled last dosing interval were not significantly different among treatment regimens, and the achieved Cmax and Tmx were also not different among treatment regimens. Rather, as there were significant differences in t1/2, it seems that an increase in apparent serum clearance is responsible for the lower AUC developed in the group receiving novobiocin-rifampin.
The mechanism of this increase in apparent serum clearance is uncertain. However, certain speculations can be made. It is well known that rifampin causes induction of the cytochrome P-450 enzyme system in the liver, as well as a proliferation of the smooth endoplasmic reticulum (3) . One may then speculate that the clearance of novobiocin may have been increased because of an increase in drug clearance due to the induction of the hepatic cytochrome P-450 system.
Unfortunately, little information is available regarding the hepatic clearance of novobiocin. In one study by Acocella and colleagues (2), less than 1% of a novobiocin dose administered either intramuscularly or orally was recovered in the bile as parent compound, as determined by a microbiologic assay. Consequently, this implies that there is a high degree of hepatic metabolism, supporting the hypothesis that hepatic enzyme induction by rifampin could account for the altered serum concentration-time profile seen with novobiocin when given in combination.
Other hypotheses, however, are tenable. If novobiocin and rifampin competed for the same serum protein-binding site, an increase in free novobiocin would result with a subsequent increase in renal clearance. In examining the rate constant derived from samples taken at only the 12-and 24-h time points, it is evident that it is similar to the rate constant derived from the study with novobiocin alone. This is consistent with the explanation given above, as rifampin concentrations declined to less than the assay sensitivity at these times. This hypothesis may have been testable by looking at fractional urinary excretion rates for novobiocin when administered alone and in combination with rifampin. Unfortunately, we did not collect this information during the course of this study. We are currently evaluating the protein binding of novobiocin alone and in the presence of rifampin.
The serum concentrations seen with rifampin administered as 300 mg twice a day were consistent with those achieved in another study (1) . The average t1/2 of 1.45 h is somewhat shorter than that seen in single dosing studies of rifampin but may be explained by the observation of the induction of rifampin of its own clearance in the multiple dosing situation. In summary, we demonstrated that the combination of rifampin-novobiocin significantly changes the serum concentration-time profile of novobiocin when compared with that achieved with novobiocin alone. However, the degree of change seen in this study is unlikely to be of clinical significance. The advantage demonstrated in vitro of the prevention of emergence of resistance to either agent gained by giving the drugs in combination outweighs the loss of serum novobiocin concentration seen with combination therapy. We conclude that novobiocin-rifampin generates a serum concentration-time curve for each agent which makes this combination potentially useful for oral therapy of methicillin-resistant S. aureus infections. On the basis of the results from this and previous microbiologic studies performed with this combination, trials for the elimination of the methicillin-resistant S. aureus colonization carrier state and for the therapy of infections caused by this organism have been initiated.
